Format

Send to

Choose Destination
See comment in PubMed Commons below
J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):142-9. doi: 10.1177/1545109711423445. Epub 2011 Oct 21.

Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.

Author information

1
1Centers for Disease Control and Prevention, Atlanta, GA, USA.

Abstract

BACKGROUND:

Few studies have evaluated the risk of nevirapine (NVP)-associated hepatotoxicity among HIV-infected pregnant women with a CD4 count ≥250 cells/mm(3).

METHODS:

We enrolled HIV-infected pregnant Kenyan women who initiated triple antiretroviral therapy (ART) at 34 weeks gestation. We compared the rates of severe hepatotoxicity (grades 3-4 hepatotoxicity) and rash-associated hepatotoxicity (rash with ≥grade 2 hepatotoxicity) with NVP and nelfinavir (NFV), respectively.

RESULTS:

We initiated triple ART in 522 pregnant women; severe hepatotoxicity and rash-associated hepatotoxicity occurred in 14 (3%) and 9 (2%) women, respectively. Women who initiated NVP had higher rates of severe hepatotoxicity (5% vs 1%; P = .03) and rash-associated hepatotoxicity (4% vs 0%; P = .003) when compared with NFV. Among women who initiated NVP (n = 254), a baseline CD4 count ≥250 cells/mm(3) was not associated with severe hepatotoxicity (5% vs 3%; P = .52) or rash-associated hepatotoxicity (4% vs 3%; P = .69).

CONCLUSION:

Nevirapine use but not CD4 count ≥250 cells/mm(3) was associated with hepatotoxicity.

PMID:
22020069
DOI:
10.1177/1545109711423445
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center